HCV / Hepatitis

The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

A new study finds that 1.4 million people aged 12-59 with current hepatitis C (HCV) infection, including over a third of them without a history of injection drug use.

The global hepatitis treatment market is more than a financial figure; it is a key area in the effort to combat the silent disease that impacts millions around the world.

A systematic review and meta-analysis finds that hepatitis B (HBV) education led by healthcare providers had the greatest impact on testing uptake.

In 2015 the country's high prevalence of chronic hepatitis C (HCV) was 5.4%, higher than the global average of 1%. In addition, Georgia saw a 67% reduction in chronic infection.

The role of Anti-HDV IgG tests in diagnosing HDV in patients with Hepatitis B, showing sensitivity and specificity, making these serological tests important for identifying this form of viral hepatitis.

The model predicts and stratifies hepatocellular carcinoma risk by analyzing serum HBV DNA levels and other factors to enhance early detection and management.

A recent study showed that an increase in anti-hepatitis E virus seroprevalence in patients with chronic inflammatory demyelinating polyneuropathy was not a consequence of intravenous immunoglobulin therapy.

Overall, findings demonstrated a 78% treatment success rate among patients who prematurely discontinued direct-acting antivirals (DAA), and even seeing a 93% success rate among those who discontinued after week 4.

Protein organization could pave the way for effective vaccine development

The gene USP26 is identified as a factor in hepatocellular carcinoma development and a potential therapeutic target.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.

The results indicate that paternal hepatitis B virus infection before pregnancy is linked to a 40% higher risk of congenital heart diseases in their children.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

With the ongoing war between Israel and Hamas, The World Health Organization reported a public health update. Officials are concerned about what is happening inside the Gaza Strip particularly around a variety of diseases and health conditions including hepatitis A, skin infections, and even polio.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Findings affirm the safety and efficacy of using HBsAg-positive donor kidneys in HBsAg-negative recipients, with no adverse effects on posttransplant outcomes.

Recent analysis suggests that stricter COVID-19 measures could have saved thousands, Danjuma Adda calls for more funding and awareness to tackle viral hepatitis, our second episode of From Pathogen to Infectious Disease podcast, and more this week.

Increased funding can lead to the development of resources like rapid diagnostic test kits and improve the overall availability of treatment for those in need.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

This upcoming Sunday, July 28, is this year’s World Hepatitis Day and it is an opportunity to raise awareness, deliver education to the masses, and continue to support the research and treatments to reduce the incidence rates of the infection.

The OraQuick HCV self-test aims to improve testing access and help individuals detect the disease affecting an estimated 58 million people worldwide.

An outside physician who was working at 3 hospitals in the Portland, Oregon area did not follow infection prevention protocols, leaving patients potentially exposed to bloodborne infections.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

Monitoring viral genetic changes in patients during ribavirin therapy could help identify those at risk for Hepatitis E Virus treatment failure.